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Background
In haploidentical-SCT male-patients with female-donors
have better prognosis compared to female-to-male-
combinations due to Y-encoded minor-histocompat-
ibility-antigens recognised by female-allo-immune
effector-lymphocytes in the context of a graft-versus-
leukaemia-(GvL)-effect. We provide data in a dog-
model that the minor-histocompatibility-antigen UTY
might be a promising target to further improve GvL-
immune-reactions after allogeneic-SCT.
Materials and methods
Canine (c) purebred-beagle-dogs’ PB and BM were stu-
died. T2-cells (HLA-A2+, TAP-deficient) were used.
These human-(h)-UTY-sequence-derived HLA-A2-bind-
ing-peptides were investigated: W248 (WMHHNMDLV),
T368 (TLAARIKFL), K1234 (KLFEMIKYC). In vitro:
Autologous-cDCs were generated with best of three
DC-methods (Calcium-Ionophore, Picibanil, Cytokines).
Generation cUTY-specific-CTLs: CD3+ T-cells were co-
cultured with autologous-mature cDCs+hUTY-peptides
(weekly restimulation for 21 days; +hIL-2, +hIL-7). Cyto-
toxicity and antigen-specificity were determined by [51Cr]-
release- and cIFN-g-ELISPOT-assays. Cells were quanti-
fied day 0 and of harvest using anti-cmAbs/hmAbs
(FACS), UTY-mRNA-expression via RT-PCR-analysis.
In vivo: A female-dog was immunised with PBMCs from
a DLA-identical-male-dog (day 0 and 14). PB-derived
T-cells were harvested 35 days post 2nd-injection followed
by analysing UTY-specific-reactivity.
Results
Female cUTY-specific-CTLs were stimulated in vitro
using autologous-DCs loaded with three HLA-A2-
restricted UTY-derived-peptides (≤2.9-fold-expansion)
and specific T-cell-responses were determined in 3/6
female-dogs. CTLs specifically recognised/lysed autolo-
gous-female peptide-loaded-DCs (900 spots/100,000
T-cells (median)/≤47.9%), but not naive autologous-
female-DCs and -monocytes (p≤0.026). They mainly
recognized BM and to a lower extent DCs, monocytes,
PBMCs and B-cells from DLA-identical-male-littermates
and peptide-loaded T2-cells in an MHC-I-restricted man-
ner (up to p≤ 0.046). UTY-mRNA was only expressed in
male-cells. A UTY-/male-specific-reactivity was also
obtained in vivo after stimulation of a female-dog with
DLA-identical-male-PBMCs.
Conclusions
We demonstrated natural UTY-processing/presentation in
dogs. Female-dog-CTLs were specifically stimulated by
HLA-A2-restricted-UTY-peptides, thereby enabling recog-
nition of DLA-identical-male-cells, mainly BM-cells.
These observations suggest UTY as a promising candi-
date-antigen to improve GvL-reactions in the course of
immunotherapy. Next-generation-sequencing and specia-
lised-bioinformatics-algorithms are now focus for human-
individualised-leukaemia-treatment (T-cell-receptor-
Profiling, detection/selection of T-cell-receptor-clones or
DC-based-immunotherapies).
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